




05-01-01

PCT

JC07 Rec'd PCT/PTO 30 APR 2001

FORM PTO 1390 (REV 10-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P02149US0
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 097830795
INTERNATIONAL APPLICATION NO. PCT/SE99/01958	INTERNATIONAL FILING DATES 29/10/1999	PRIORITY DATE CLAIMED 30 October 1998	
TITLE OF INVENTION LIQUID MICROVOLUME HANDLING SYSTEM			
APPLICANT(S) FOR DO/EO/US Mårten Stjernström			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).			
Items 11 to 16 below concern document(s) or information included:			
<ol style="list-style-type: none">11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.14. <input type="checkbox"/> A substitute specification.15. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter.16. <input type="checkbox"/> Other items or information:			

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 09/830795	INTERNATIONAL APPLICATION NO. PCT/SE99/01958	ATTORNEY'S DOCKET NUMBER P02149US0																																																																	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 1,000.00 Surcharge of \$ _____ for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)). <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;"></th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>13-20 =</td> <td></td> <td>x</td> <td>\$ 0.00</td> </tr> <tr> <td>Independent claims</td> <td>3-3 =</td> <td></td> <td>x</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(s) (if applicable)</td> <td>x \$</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 1,000.00</td> </tr> <tr> <td colspan="4"> <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above Are reduced by 1/2. </td> <td>\$ 500.00</td> </tr> <tr> <td colspan="4">SUBTOTAL =</td> <td>\$ 500.00</td> </tr> <tr> <td colspan="4"> Processing fee of \$ _____ for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). + </td> <td>\$</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE =</td> <td>\$ 500.00</td> </tr> <tr> <td colspan="4"> Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) (\$40.00 per property). + </td> <td>\$ 40.00</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED =</td> <td>\$ 500.00</td> </tr> <tr> <td colspan="4"></td> <td style="text-align: right;"> Amount to be Refunded: \$ </td> </tr> <tr> <td colspan="4"></td> <td style="text-align: right;"> Charged: \$ 540.00 </td> </tr> </tbody></table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		Total claims	13-20 =		x	\$ 0.00	Independent claims	3-3 =		x	\$ 0.00	MULTIPLE DEPENDENT CLAIM(s) (if applicable)				x \$	TOTAL OF ABOVE CALCULATIONS =				\$ 1,000.00	<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above Are reduced by 1/2.				\$ 500.00	SUBTOTAL =				\$ 500.00	Processing fee of \$ _____ for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				\$	TOTAL NATIONAL FEE =				\$ 500.00	Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) (\$40.00 per property). +				\$ 40.00	TOTAL FEES ENCLOSED =				\$ 500.00					Amount to be Refunded: \$					Charged: \$ 540.00	CALCULATIONS PTO USE ONLY
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																																
Total claims	13-20 =		x	\$ 0.00																																																															
Independent claims	3-3 =		x	\$ 0.00																																																															
MULTIPLE DEPENDENT CLAIM(s) (if applicable)				x \$																																																															
TOTAL OF ABOVE CALCULATIONS =				\$ 1,000.00																																																															
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above Are reduced by 1/2.				\$ 500.00																																																															
SUBTOTAL =				\$ 500.00																																																															
Processing fee of \$ _____ for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				\$																																																															
TOTAL NATIONAL FEE =				\$ 500.00																																																															
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) (\$40.00 per property). +				\$ 40.00																																																															
TOTAL FEES ENCLOSED =				\$ 500.00																																																															
				Amount to be Refunded: \$																																																															
				Charged: \$ 540.00																																																															
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>06-2375</u> in the amount of \$ <u>540.00</u> To cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required or credit Any overpayment to my Deposit Account No. <u>06-2375</u> . A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status. SEND ALL CORRESPONDENCE TO: Melissa W. Acosta FULBRIGHT & JAWORSKI L.L.P. 1301 McKinney, Suite 5100 Houston, Texas 77010-3095 (713) 651-5407																																																																			
<div style="text-align: right;">  SIGNATURE: _____ NAME: _____ REGISTRATION NUMBER: <u>45,872</u> </div>																																																																			
EXPRESS MAIL NO. EH244916493US																																																																			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	§	Docket No.: P02149US0
	§	
Filing Date: 04/30/01	§	
	§	Examiner:
Applicant: Mårten Stjernström	§	
	§	
Title: Liquid Microvolume Handling System	§	Art Unit:
	§	

Box Application
Assistant Commissioner of Patents and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please enter the following amendments to the claims prior to examination.

In the claims:

Please substitute the following amended claims contained herein for claims 1-9 that were in the original PCT application.

1. (Amended) A microfluidic device comprising a microchannel, providing for liquid contact between an open microarea or chamber suitable for carrying a microvolume of a solvent and a reservoir for the solvent, said reservoir and said microchannel being adapted so that solvent evaporated from said microarea is able to be continuously replaced by solvent from the reservoir through said microchannel.

2. (Amended) The microfluidic device according to claim 1 wherein

a) said reservoir is positioned so as to create an overpressure in the solvent which is in equilibrium with the interfacial pressure difference across the curved surface of the droplet, or

b) said reservoir is connected to pump means that either facilitate replacement of solvent by pumping solvent or pressurising the reservoir.

3. (Amended) The microfluidic device according to claim 1 comprising a plurality of microchannels and open chambers forming an array in the circular or rectangular format.
4. (Amended) The microfluidic device according to claim 1, wherein the microvolume contains one or more reactants that are soluble in the solvent or bound to a solid support in contact with the microvolume.
5. (Amended) The microfluidic device according to claim 4 wherein at least one of said one or more reactants is an affinity reactant selected from the group consisting of nucleic acids, peptides, and proteins.
6. (Amended) A method for replacing solvents evaporating from a microvolume of solvent placed in an open microarea of a microfluidic device comprising the step of replacing solvent continuously via a microchannel that transports liquid to the microarea from a liquid reservoir.
7. (Amended) The method of claim 6, wherein the microarea, microchannel and reservoir are parts of a microfluidic device.
8. (Amended) A method for replacing solvents for preventing samples from becoming desiccated comprising the following steps:
 - providing a microarea for receiving a sample;
 - connecting the microarea to a reservoir of solvent by a microchannel;
 - applying the sample to the microarea;
 - allowing solvent to evaporate from said microarea; and
 - continuously replacing said evaporated solvent with solvent from said reservoir.
9. (Amended) The method of claim 8 further comprising the step of anchoring the sample to the microarea.

Please add the following new claims.

10. (New) The method of claim 7, wherein the reservoir is positioned so as to create an overpressure in the solvent which is in equilibrium with the interfacial pressure difference across the curved surface of the droplet or said reservoir is connected to pump means that either facilitate replacement of solvent by pumping solvent or pressurising the reservoir.
11. (New) The method of claim 7, wherein the microfluidic device comprises a plurality of microchannels and open chambers forming an array in the circular or rectangular format.
12. (New) The method of claim 7, wherein the microarea carries a microvolume containing one or more reactants that are soluble in the solvent or bound to a solid support in contact with the microvolume.
13. (New) The method of claim 12, wherein at least one of said one or more reactants is an affinity reactant selected from the group consisting of nucleic acids, peptides, and proteins.

REMARKS

Claims 1-9 were in the original PCT application as filed. Applicant has amended claims 1-9 to delete the multiple dependency. Applicant has also added new claims 10-13, which relates to the subject matter that was contained in the multiple dependent claims of the PCT application. Applicant has included a marked up version of the claims as amended herein as Appendix A. For the convenience of the Examiner, Applicant has provided a clean copy of all pending claims as of the date of this preliminary amendment. Applicant asserts that no new matter has been added.


CONCLUSION

Claims 1-9 were in the original PCT application. Applicants have amended claims 1-9 to delete the multiple dependency and have added new claims 10-13 which related to the subject matter in the original multiple dependent claims. Therefore,

these amendments do not narrow the scope of the claims within the meaning of *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd.*, 234 F.3d 558, 586, 56 USPQ2d 1865, 1886 (Fed. Cir. 2000).

Applicant does not believe that there is a fee required to file this preliminary amendment. If applicant is in error, applicant authorizes the Commissioner to charge any required fees to the Deposit Account No. 06-2375/10102583, from which the undersigned is authorized to draw.

Respectfully submitted,


Melissa W. Acosta, Ph.D.
Registration No. 45,872

Date: April 30, 2001

Fulbright & Jaworski, L.L.P.
1301 McKinney, Suite 5100
Houston, Texas 77010-3095
(713) 651-5407 Telephone
(713) 651-5246 Facsimile

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) A microfluidic device comprising a microchannel [(2, 4)], providing for liquid contact between an open microarea [(MA)] or chamber suitable for carrying a microvolume [(1)] of a solvent and a reservoir [(3, 8)] for the solvent, said reservoir [(3, 8)] and said microchannel [(2, 4)] being adapted so that solvent evaporated from said microarea [(MA)] is able to be continuously replaced by solvent from the reservoir [(3, 8)] through said microchannel[(2, 4)].
2. (Amended) The microfluidic device according to claim 1 wherein
 - a) said reservoirvessel [(3, 8)] is positioned so as to create an overpressure in the solvent which is in equilibrium with the interfacial pressure difference across the curved surface of the droplet, or
 - b) said reservoir [(3, 8)] is connected to pump means that either facilitate replacement of solvent by pumping solvent or pressurising the reservoir[(3, 8)].
3. (Amended) The microfluidic device according to [anyone of] claim[s] 1[-2] comprising a plurality of microchannels [(3, 8)] and open chambers forming an array in the circular or rectangular format.
4. (Amended) The microfluidic device according to [anyone of] claim[s] 1[-3], wherein the microvolume contains one or more reactants that are soluble in the solvent or bound to a solid support in contact with the microvolume.
5. (Amended) The microfluidic device according to claim 4 wherein at least one of said one or more reactants is an affinity reactant[, for instance] selected from the group consisting of nucleic acids, peptides, and proteins.
6. (Amended) A method for replacing solvents evaporating from a microvolume of solvent placed in an open microarea [(MA)] of a microfluidic device comprising the step of [characterised in that that replacement] replacing [is] solvent continuously

[taking place] via a microchannel [(2, 4)] that transports liquid to the microarea [(MA)] from a liquid reservoir [(vessel) (3, 8)].

7. (Amended) The method of claim 6, wherein the [characterised in that] the microarea [(MA)] , microchannel [(2, 4)] and reservoir are parts of a microfluidic device [defined in claims 1-5].

8. (Amended) A [M]method for replacing solvents for preventing samples from becoming desiccated [characterised in that it comprises] comprising the following steps:

providing a microarea (MA) for receiving a sample;

connecting the microarea [(MA)] to a reservoir [(3, 8)] of solvent by a microchannel [(2, 4)];

applying the sample to the microarea [(MA)];

allowing solvent to evaporate from said microarea [(MA)]; and

continuously replacing said evaporated solvent with solvent from said reservoir [(3, 8)].

9. (Amended) The [M]method [in accordance with] of claim 8 further comprising the step of [characterised in that it comprises the additional step of:] anchoring the sample to the microarea [(MA)].

10. (New) The method of claim 7, wherein the reservoir is positioned so as to create an overpressure in the solvent which is in equilibrium with the interfacial pressure difference across the curved surface of the droplet or said reservoir is connected to pump means that either facilitate replacement of solvent by pumping solvent or pressurising the reservoir.

11. (New) The method of claim 7, wherein the microfluidic device comprises a plurality of microchannels and open chambers forming an array in the circular or rectangular format.

12. (New) The method of claim 7, wherein the microarea carries a microvolume containing one or more reactants that are soluble in the solvent or bound to a solid support in contact with the microvolume.

13. (New) The method of claim 12, wherein at least one of said one or more reactants is an affinity reactant selected from the group consisting of nucleic acids, peptides, and proteins.

098075 04300
"5620E360

APPENDIX B

CLEAN COPY OF PENDING CLAIMS AS OF PRELIMINARY
AMENDMENT DATED APRIL 30, 2001

1. A microfluidic device comprising a microchannel, providing for liquid contact between an open microarea or chamber suitable for carrying a microvolume of a solvent and a reservoir for the solvent, said reservoir and said microchannel being adapted so that solvent evaporated from said microarea is able to be continuously replaced by solvent from the reservoir through said microchannel.
2. The microfluidic device according to claim 1 wherein
 - a) said reservoir is positioned so as to create an overpressure in the solvent which is in equilibrium with the interfacial pressure difference across the curved surface of the droplet, or
 - b) said reservoir is connected to pump means that either facilitate replacement of solvent by pumping solvent or pressurising the reservoir.
3. The microfluidic device according to claim 1 comprising a plurality of microchannels and open chambers forming an array in the circular or rectangular format.
4. The microfluidic device according to claim 1, wherein the microvolume contains one or more reactants that are soluble in the solvent or bound to a solid support in contact with the microvolume.
5. The microfluidic device according to claim 4 wherein at least one of said one or more reactants is an affinity reactant selected from the group consisting of nucleic acids, peptides, and proteins.
6. A method for replacing solvents evaporating from a microvolume of solvent placed in an open microarea of a microfluidic device comprising the step of replacing solvent continuously via a microchannel that transports liquid to the microarea from a liquid reservoir.

- #25018631

09/830795

LIQUID MICROVOLUME HANDLING SYSTEM

PCT/PCT Rec'd 30 APR 2001

TECHNICAL FIELD

- 5 The present invention relates to microfluidic devices comprising microchannels, and to methods for replacing solvent amounts that evaporate from open microareas carrying microvolumes of the solvent. The present invention also relates to the use of the method for replacing solvent in a method for preventing the desiccation of samples. The microvolume of solvent may be in the form of a droplet (microdrop).

10

BACKGROUND ART

- Microvolume handling systems have attracted a considerable interest in biochemical analysis, combinatorial chemistry and high throughput screening (HTS) applications. The miniaturised format is compatible in size with many interesting issues of bioanalytical work, such as single cell analysis, when material is available only in extremely limited amounts. Furthermore, by decreasing the volume, an enhanced efficiency in terms of a higher rate of mixing and/or chemical reaction can be expected in the sample container, since the effect of diffusion and thermal convection is more pronounced on a smaller scale.

- In HTS applications, goals are currently set on screening more than 10^5 compounds in a single assay. To manage such a tremendous number of samples with reasonable space, cost and time requirements, the miniaturised microtitre plate format has been developed. Based on micromachining of different materials, e.g., by anisotropically etching single crystalline silicon wafers, well-defined picolitre to nanolitre vials are readily fabricated (Jansson et al. (1992) J. Chromatography 626, 310-314; Beyer Hietpas et al. (1995) J. Liq. Chromatography 18, 3557-3576). Biomolecules such as DNA and proteins have been assayed in the microvial format utilising capillary electrophoresis (Jansson et al. *supra*; Beyer Hietpas et al., *supra*), bioluminescence (Crofcheck et al. (1997) Anal. Chem. 69, 4768-4772), electrochemical analysis (Clark et al. (1997) Anal. Chem. 69, 259-263; Clark et al. (1998) Anal. Chem. 70, 1119-1125) and mass spectrometry (Jespersen et al. (1994) J. Rapid Comm. in Mass Spectrom. 8, 581-584).

However, the rate of solvent evaporation is particularly pronounced for microvolumes, for instance small droplets, since the surface-to-volume ratio increases when the drop diameter decreases. The most common way for avoiding
5 desiccation is by covering the containers with a material non-permeable for the underlying solvent. However, covers, either liquid or solid, inherently have the potential to introduce interfering compounds, or to alter equilibriums, that can seriously damage sensitive chemical systems. Furthermore, practical problems may arise from small droplets sticking to a solid cover.

10

An alternative is to diminish the solvent loss by controlling the environment in humidified chambers and by dispensing compensating solvent into the microvials
15 via fine capillaries from above (Roeraade et al. (1996) Analytical Methods and Instrumentation. Special issue μ TAS'96 (1996), pp. 34-38). However, this technique can be ineffective over prolonged time periods and is subject to many practical problems associated with the restricted accessibility to the vials through the environmental chamber. Furthermore, since the solvent compensating capillaries block the space in close proximity to the microvials, accessing or detecting the material becomes increasingly more complex as the assay becomes larger.

20

There is a need for microfluidic devices including a system for handling small volumetric amounts of liquid which avoids the above discussed drawbacks and allows for free access to the contained material, thus facilitating chemical
25 manipulation of the liquid or the gaseous headspace environment and for monitoring of reaction products.

A device having the features of claim 1 and a method having the features of claim 6 fulfill this need.

30 BRIEF DESCRIPTION OF THE DRAWINGS

Examples of embodiments of the present invention are illustrated in the accompanying figures, where:

5 Figure 2 is an enlarged view of the top of the capillary in Figure 1 illustrating a droplet;

Figure 3 illustrates the three different possible shapes of the liquid-gaseous interface:

Figure 4 illustrates a top of an embodiment of a microchannel in accordance with the present invention with a droplet and sample components immobilised on the microchannel rim:

15 Figure 5 illustrates a circular array of fabricated holes containing microdrops in accordance with other embodiment of the present invention;

Figure 6 is a sectional view of Figure 3 illustrating a solvent container in accordance with an embodiment of the present invention:

Figure 7 is a schematic view of a rectangular array in accordance with the present invention;

Figure 8 is a sectional view of the array of Figure 7.

25

DISCLOSURE OF THE INVENTION

SUBSTITUTE SHEET (RULE 26)

analyte and/or various reagents, may be soluble in the microvolume or immobilised to a solid support in contact with the microvolume. The microarea (MA) may be the orifice region of the microchannel and the microvolume in the form of a microdrop (1), as shown in Figure 2. By continuously replacing the evaporated solvent via a conduit (2) with solvent from a communicating vessel (3) the reactants present in the microvolume are prevented from being desiccated. The sample is focused in the microvolume as long as the evaporation rate of the solvent is higher than the sample diffusion rate. It should be noted that the solvent compensating principle is generally applicable to minute volumes, thus the liquid-gaseous interface may appear in any of the different shapes illustrated in Figures 3 a)-c). In the case of droplets shown figure 3 a), they can be formed by applying an overpressure to the solvent supplying tubing. This causes the droplet size to be determined by the diameter of the capillary orifice, the interfacial tension, the wettability of the capillary material and the magnitude of the applied overpressure (which needs to be in equilibrium with the interfacial pressure difference across the curved surface of the droplet). The microarea (MA) can be located either, as illustrated in Figure 1, on top of a single capillary (4), or as shown in Figures 5 – 8, as an array of microareas carrying liquid in the form of drops (6) or liquid in the form of other physical microappearances (9) (e.g. surfaces of the type shown in figures 3 b)-c)) formed on top of an array of fabricated holes (7) each supplied from a common solvent container (8). In the case of droplets, the overpressure needed can be created by any means of pressure generation, e.g. from a hydrostatic head, a micropump or a pressurised container.

The open geometry in this invention, with microareas carrying analyte- and/or reagent-containing solvent in direct contact with the surrounding gaseous phase, is favourable with respect to easy accessibility. For example, wet-chemical reactions can easily be performed with sample components contained in the surface layers, using reagents dispensed from external means directly to the microvolume of liquid placed in the microarea, for instance from ink-jet dispensers or fine pipettes. Furthermore, detection of analytes or reaction products can readily be made by using optical detectors, such as CCD-cameras. Moreover, the equilibrium between the solvent on the microarea and the surrounding gaseous phase could be

exploited for passive sampling of air-born constituents over prolonged time periods, thus enabling subsequent environmental analysis.

The solvents contemplated are often aqueous, i.e. consists of water, possibly mixed
5 with one or more water-miscible liquids, such as acetone, methanol, ethanol and isopropanol. This does not exclude the use of other solvents in the invention.

A second aspect of the invention relates to a microfluidic device comprising a microchannel providing for liquid contact between an open microarea carrying a
10 microvolume of a solvent and a reservoir for the solvent, said reservoir and said microchannel being adapted so that solvent evaporated from said microarea is continuously replaced by solvent from the reservoir through said microchannel. When in use the microvolume of solvent typically contains an analyte and/or one or more reagents for assaying the analyte either directly or indirectly, for running
15 synthesis of a compound etc. By the term "indirectly" is contemplated that a feature or an amount of a reaction product related to the analyte is assayed.

In order to avoid the risk of desiccation of the microareas over prolonged time periods, the supplying solvent vessel should contain a solvent volume one, two
20 three or more orders of magnitude larger than the sum of all microvolumes communicating with the reservoir.

The term "microvolume" means a volume that typically is at most around 10 μl , such as $\leq 1 \mu\text{l}$. The lower end of the range extends down to the infinitesimal volume that
25 is present in the gaseous-liquid interface of the microvolume of the solvent.

Typically the microvolume is $\geq 10^{-15}$ l (femtolitre). It will be understood, however, that the described principles may be applicable also to microvolumes being larger than 10 μl . By "microfluidic device" is meant a device that can handle microvolumes, for example a volume that is less than 1 μl , preferably between 1
30 and 10 nl, of reagents that may be introduced into the device.

A microarea may have different forms that vary from being an essentially flat form via cup-formed areas to being walls of open chambers, the important matter being that the area is able to carry the microvolume of liquid contemplated.

Microchannels typically have the ability to act as capillaries. Normally their size in the dimension (i.e. height, width or length) in which they are smallest is less than 2000 μm , such as $\leq 500 \mu\text{m}$. Typically this dimension is $\geq 1 \mu\text{m}$. A microchannel
5 may be in form of a tube that may have a circular, a rectangular etc cross sectional area. They may also be "sheet"-like covering larger areas.

The reagents included in or in contact with the microvolume of solvent vary depending on the reaction to be run. The reagents include catalysts, for instance,
10 an enzyme, compounds needed for the synthesis of nucleic acids, affinity reactants, etc. The term also includes biological systems, such as enzymatic systems and whole cells. Affinity reactants typically form non-covalent complexes and may be illustrated by biotin, streptavidin, protein A, antibodies, lectins, hormone receptors, nucleic acids, peptides and polypeptides. Typical assays are immunoassays,
15 sequenceing of nucleic acids and of peptides, hybridisation assays, detection of mutations, cell assays, etc.

In one embodiment of the invention, one or more of the reagents used are immobilised in the microarea (MA). This alternative configuration is illustrated in
20 Figure 4, where reagents (11) are immobilised on the rim (5) of a microchannel, allowing washing steps to be performed by overflowing the microchannel. Immobilisation may be achieved via covalent bonds, affinity bonds, physical adsorption etc. Typical affinity bonds are those formed by having strepavidin or a high affinity antibody bound to a solid support in the microarea (MA) and then
25 binding a desired reagent conjugated with biotin or with the hapten against which the antibody is specific to the solid support bound strepavidin/high affinity antibody.

The method for replacing solvents can be used in a method to prevent samples from becoming desiccated. One example of a method for achieving this comprises
30 the following steps:

- providing a microarea for receiving a sample;
- connecting the microarea (preferably via a microchannel) to a reservoir of solvent;
- applying the sample to the microarea;

allowing solvent to evaporate from said microarea; and
continuously replacing said evaporated solvent with solvent from said reservoir.

In this example, it is preferable that the diffusion rate of the sample in the solvent
5 is less than the flow rate of solvent from the reservoir so that the sample does
not diffuse away from the microarea.

A second example of a method for preventing samples becoming desiccated
comprises the additional step of:

10 anchoring the sample to the microarea.

In this example, the flow rate of solvent from the reservoir may be less than the
diffusion rate of the sample in the solvent once the sample is firmly attached to the
microarea and is unable to diffuse away.

15 The sample can be applied to the microarea by dispensing from above, for
example by dropping into the microarea a drop of solvent containing the sample,
or from below, for example by injecting the sample into the microchannel
between the reservoir and the microarea and allowing the flow of solvent to bring
20 the sample to the micro area.

The microfluidic device according to the invention can suitably be fabricated in the
form of a circular (Figure 5 and 6) or rectangular array format (Figure 7 and 8),
although any other shape is also conceivable.

25 A circular format means that there are one or more microareas (chambers) that are
placed radially and in different directions from a centre. The distance from the
centre to individual microareas (chambers) may be equal or different. The reservoir
is preferably in the centre. The microchannels may be radially directed from the
30 centre and communicate with one or more microareas. The microchannels may
also be in the form of a common, flat-like microchannel or reservoir beneath the
microareas (chambers) and communicating upwardly via traditional microchannels.

In rectangular formats there are microareas (chambers) that form a rectangular pattern. The microchannel arrangement may be in analogy with the circular format.

Microfluidic devices in the form of rotatable discs are known in the art. WO

5 97/21090 discloses a microanalytical / microsynthetic system for biological and chemical analysis, comprising a rotatable microplatform, e.g. a disc, having inlet ports, microchannels, detection chambers (microareas) and outlet ports through which fluid may flow. Preferably, a circular array comprises a disc and a plurality of microchannels (see Figure 5 and 6), each microchannel being radially dispersed
10 about the centre of the said rotatable disc. The rotatable disc is adapted for rotation about its axis. Such adaptation may take the form of a hole at the axis of one or both substrates which is capable of engaging a drive shaft. Other methods of rotating the disc include clamping the disc and contacting the perimeter with a moving surface, for example moving wheels, or placing the disc on a turntable and
15 spinning the turntable. Preferably the disc comprises a solvent inlet port located towards the centre of the disc and connected to radially dispersed microchannels, each microchannel having a sample reservoir located at the microchannel orifice that is located outward from the centre of the disc.

20 The configuration of the microchannels in the rectangular or circular format may be chosen to allow for application of a chemical compound, or a suspension of cells, to the sample reservoir filled with fluid medium.

The microfluidic device may also comprise a separate microchannel system for
25 transporting one or more of the reactants needed to the microareas.

Suitably the circular or rectangular array format is a one- or two-piece construction assembled together to provide a closed structure with openings at defined positions to allow loading of the device with liquids and removal of waste liquids. In the
30 simplest form, see, for example, figures 6-7, the disc or wafer is produced as two complementary parts (12), (13), one or each carrying channel structures which, when affixed together, form a series of interconnected structures within the body of a solid disc or wafer. The microchannels may be formed by micro-machining methods in which the channels and chambers are micro-machined into the surface

of a disc or wafer, and a cover, for example a plastic film, is adhered to the surface so as to enclose the channels and chambers.

Suitable glass or polymeric materials can be additionally selectively modified by
5 chemical or physical means to alter the surface properties to confer a desired property, e.g. compatibility with cell growth, cell attachment and the attachment of biomolecules by covalent or non-covalent means.

Based on knowledge at the priority date, the variant given in figures 1 and 2
10 corresponds to the best mode in October 1998.

09830795-043001
T00E40" 56700060

CLAIMS

1. A microfluidic device comprising a microchannel (2, 4), providing for liquid contact between an open microarea (MA) or chamber suitable for carrying a microvolume (1) of a solvent and a reservoir (3; 8) for the solvent, said reservoir (3; 8) and said microchannel (2, 4) being adapted so that solvent evaporated from said microarea (MA) is able to be continuously replaced by solvent from the reservoir (3; 8) through said microchannel (2, 4).
2. The microfluidic device according to claim 1 wherein
- a) said reservoir (3; 8) is positioned so as to create an overpressure in the solvent which is in equilibrium with the interfacial pressure difference across the curved surface of the droplet, or
 - b) said reservoir (3; 8) is connected to pump means that either facilitate replacement of solvent by pumping solvent or pressurising the reservoir (3; 8).
3. The microfluidic device according to anyone of claims 1-2 comprising a plurality of microchannels (3; 8) and open chambers forming an array in the circular or rectangular format.
4. The microfluidic device according to anyone of claims 1-3, wherein the microvolume contains one or more reactants that are soluble in the solvent or bound to a solid support in contact with the microvolume.
5. The microfluidic device according to claim 4 wherein at least one of said one or more reactants is an affinity reactant, for instance selected from nucleic acids, peptides, proteins.
6. A method for replacing solvents evaporating from a microvolume of solvent placed in an open microarea (MA) of a microfluidic device, characterised in that that replacement is continuously taking place via a microchannel (2, 4) that transports liquid to the microarea (MA) from a liquid reservoir (vessel) (3; 8).

11

7. The method of claim 6, characterised in that the microarea (MA), microchannel (2, 4) and reservoir are parts of the microfluid device defined in claims 1-5.

8. Method for replacing solvents for preventing samples from becoming desiccated
5 characterised in that it comprises the following steps:
providing a microarea (MA) for receiving a sample;
connecting the microarea (MA) to a reservoir (3; 8) of solvent by a
microchannel (2, 4);
applying the sample to the microarea (MA);
10 allowing solvent to evaporate from said microarea (MA); and
continuously replacing said evaporated solvent with solvent from said
reservoir (3; 8).

9. Method in accordance with claim 8 characterised in that it comprises the
15 additional step of:
anchoring the sample to the microarea (MA).





Fig. 3






Fig. 5




Fig. 6






Fig. 7**Fig. 8**

Please type a plus sign (+) inside this box



PTO/SB/01 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	P02149US0
First Named Inventor	Mårten Stjernström
COMPLETE IF KNOWN	
Application Number	Not Yet Assigned
Filing Date	
Group Art Unit	N/A
Examiner Name	Not Yet Assigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

LIQUID MICROVOLUME HANDLING SYSTEM

(Title of the Invention)

the specification of which

☒ is attached hereto
OR

☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application No. and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/SE99/01958 9803734-4	PCT	10/29/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	SE	10/30/1998	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. CH244916493US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: April 2nd, 2001 Signature: Melissa W. Acosta (Melissa W. Acosta)

Please type a plus sign (+) inside this box ☐

PTO/SB/01 (03-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input type="checkbox"/> Customer Number or Bar Code Label		<input checked="" type="checkbox"/> Correspondence address below	
Name <u>FULBRIGHT & JAWORSKI L.L.P.</u> <u>Melissa W. Acosta</u>			
Address <u>1301 McKinney, Suite 5100</u>			
City <u>Houston</u>	State <u>TX</u>	ZIP <u>77010-3095</u>	
Country <u>US</u>	Telephone <u>(713) 651-5151</u>	Fax <u>(713) 651-5246</u>	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.			
NAME OF SOLE OR FIRST INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any]) <u>Mårten</u>		Family Name or Surname <u>Stjernström</u>	
Inventor's Signature <u>[Signature]</u>		Date <u>2001-04-18</u>	
Residence: City <u>Stockholm</u>	State <u>SE</u>	Country <u>Sweden</u>	Citizenship
Mailing Address: <u>Styrmansgatan 23</u>			
City <u>Stockholm</u>	State	ZIP <u>S-114 54</u>	Country <u>Sweden</u>
NAME OF SECOND INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address:			
City	State	ZIP	Country
<input type="checkbox"/> Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.			

POWER OF ATTORNEY


GYROS AB, Uppsala Science Park, SE 751-83 Uppsala, Sweden, assignee of all right, title and interest in the enclosed patent application, hereby appoints the following agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Ronald G. Bliss	Reg. No. <u>28,691</u>
Paul E. Krieger	Reg. No. <u>25,886</u>
Robert J. Koch	Reg. No. <u>26,637</u>
Paul L. Deverter	Reg. No. <u>19,747</u>
James W. Repass	Reg. No. <u>30,487</u>
Thomas D. Paul	Reg. No. <u>32,714</u>
Marc L. Delflache	Reg. No. <u>28,942</u>
David L. Fox	Reg. No. <u>40,612</u>
Jan K. Simpson	Reg. No. <u>33,283</u>
John M. Mings	Reg. No. <u>35,955</u>
Mark E. Ungerman	Reg. No. <u>32,070</u>
Peter J. Davis	Reg. No. <u>36,119</u>
Scott Denko	Reg. No. <u>37,606</u>
Charles B. Walker, Jr.	Reg. No. <u>43,231</u>
Richard S. Zembek	Reg. No. <u>43,306</u>
Alberto Amatong	Reg. No. <u>41,580</u>
Gino Catena	Reg. No. <u>45,546</u>
Melissa Acosta	Reg. No. <u>45,872</u>
Melissa Schwaller	Reg. No. <u>46,089</u>
Melissa Sistrunk	Reg. No. <u>45,579</u>
Michael S. McCoy	Reg. No. <u>P-46,913</u>
Eric Hall	Reg. No. <u>P-46,751</u>

Address all correspondence to Patent Department; Fulbright & Jaworski L.L.P., 1301

McKinney, Suite 5100, Houston, Texas 77010-3095.

GYROS AB


M. Hartman

DATE: April 11, 2001